ST. PAUL, Minn., Jan. 7, 2014 /PRNewswire/ -- Data Sciences International (DSI) announces it has acquired Buxco Research Company. The acquisition will combine Buxco's expertise in preclinical pulmonary research with DSI's leadership in designing and manufacturing implantable telemetry devices to provide researchers a world class physiologic monitoring solution. The companies' combined capabilities will support greater productivity for cardiopulmonary researchers.
The transaction will create an unrivaled leader in serving the preclinical physiologic monitoring market. The combination builds on both companies' technological strengths to accelerate results for life sciences customers working in cardiovascular and pulmonary research.
"We are extremely excited about this acquisition because it helps DSI realize our vision of being a solutions provider for our customers and creates significant value for our shareholders," said Bert Harman chief executive officer for DSI. "Our customers will now be able to achieve even higher levels of productivity by working with DSI. For our shareholders, we expect the transaction to generate attractive financial returns."
DSI is a pioneering biomedical research company focused on pre-clinical systems physiology and pharmacology. The recognized global leader in physiologic monitoring, DSI offers telemetry, instrumentation, software and services that help advance science. DSI serves many industries including: Pharmaceuticals, Academia, Contract Research Organizations, Biological and Chemical Defense, the Medical Device Industry, Government, and Biotechnology companies. Solutions are tailored specifically to meet the unique research needs of their customers.
Visit http://www.datasci.com for more about the company.
SOURCE Data Sciences International